Evidence map›Paper›PMID 40833185›Full record

ArticleJournal of veterinary internal medicine

Fecal and Clinical Profiles of Dogs With Chronic Enteropathies Treated With Bile Acid Sequestrants for 5-47 Months: A Retrospective Case Series.

Linda Toresson, Amanda B Blake, Chi-Hsuan Sung, Gunilla Olmedal, Ulrika Ludvigsson, Paula R Giaretta, M Katherine Tolbert, Jan S Suchodolski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Linda ToressonGastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0003-2003-9554
Amanda B BlakeGastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0002-0866-6662
Chi-Hsuan SungGastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, USA.
Gunilla OlmedalEvidensia Specialist Animal Hospital, Helsingborg, Sweden.
Ulrika LudvigssonEvidensia Specialist Animal Hospital, Helsingborg, Sweden.ORCID https://orcid.org/0009-0005-4686-1708
Paula R GiarettaGastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0003-2261-281X
M Katherine TolbertGastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0001-8725-9530
Jan S SuchodolskiGastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, USA.ORCID https://orcid.org/0000-0002-2176-6932

Funding

Purina PetCare Research Excellence FundSwedish Veterinary Care FoundationUlla Yard Foundation
6 · The paper itself

Abstract

backgroundBile acid (BA) malabsorption and BA diarrhea (BAD) are prevalent but underdiagnosed conditions in people with chronic diarrhea of multiple causes. Recent studies have shown BA dysmetabolism in dogs with chronic enteropathies (CE).

objectiveDescribe canine inflammatory bowel disease activity index (CIBDAI), dysbiosis index (DI) and fecal BA concentrations in healthy dogs and dogs with refractory or partially immunosuppressive-responsive CE or CE dogs requiring high doses of corticosteroids, treated with BA sequestrants (BAS). ANIMALS: Twenty-four CE dogs and 18 healthy dogs.

methodsRetrospective case series. Dogs with CE were treated with BAS as adjunctive treatment. Fecal BA was analyzed using liquid chromatography-tandem mass spectrometry. Fecal microbiota was assessed using DI. Response to treatment was defined as a decrease in CIBDAI category.

resultsSixteen of 24 dogs improved clinically after BAS treatment (cholestyramine, 44-133 mg/kg q12h; colesevelam, 7-24 mg/kg q12h; colestipole, 26 mg/kg q24h). Duration of treatment was 5-47 months. Median (range) CIBDAI decreased from 6.5 (4-13) to 3 (2-5) in responders. At baseline, responders had a higher median (range) percentage of fecal unconjugated primary BAs (93 [1-100]) versus non-responders (2.5 [0-95]) and healthy dogs (1.5 [0-19]). Dysbiosis index (median [range]) was higher in responders (4.2 [-4.7 to 9.0]) versus non-responders (-0.1 [-1.5 to 5.7]) and healthy dogs (-4.5 [-6.4 to -0.2]). CONCLUSIONS AND CLINICAL IMPORTANCE: Treatment with BAS as adjunctive treatment potentially may benefit some dogs with nonresponsive or partially immunosuppressive-responsive enteropathy or CE dogs requiring high doses of corticosteroids.

Indexed as

Bile Acids and SaltsDog DiseasesFecesInflammatory Bowel DiseasesIntestinal DiseasesAnimalsCholestyramine ResinChronic DiseaseColesevelam HydrochlorideDiarrheaDogsFemaleMaleRetrospective StudiesBile Acids and SaltsCholestyramine ResinColesevelam Hydrochloridebile acid diarrheabile acid dysmetabolismcholestyraminecolesevelamnon‐responsive enteropathy

Identifiers

PMID40833185
PMCPMC12365994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.